Study S001409
A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)
Registration
Registered primary outcomes
- Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30 [Baseline, Week 30]
Linked records (17)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0048087 | Vergleich von iGlarLixi mit einem Basal-Bolusregime bei Patienten mit Typ-2-Diabetes mittels Propensity-Score-Matching (PSM) JJ Meier, Diabetologie und Stoffwechsel | 2021 | Nonrandomized study | DOI | cites ClinicalTrials.gov:NCT02058160 |
| R0048976 | Einfluss der Typ-2-Diabetesdauer auf die Wirkung von iGlarLixi gegenüber Insulin glargin 100 E / ml bei einer basalunterstützten oralen Therapie (BOT): Eine Subanalyse der LixiLan-L-Studie Jochen Seufert, Diabetologie und Stoffwechsel | 2021 | Other | DOI | cites ClinicalTrials.gov:NCT02058160 |
| R0011584 | Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. Davidson JA, Diabetic medicine : a journal of the British Diabetic Association | 2020 | Other trial | PMID 31365765DOI | cites ClinicalTrials.gov:NCT02058160 |
| R0015456 | Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis. Tabák ÁG, Diabetes therapy : research, treatment and education of diabetes and related disorders | 2020 | Randomized trial | PMID 31848983DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:31848983 |
| R0007277 | EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES. Mora PF, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists | 2019 | Randomized trial | PMID 31241362DOI | cites ClinicalTrials.gov:NCT02058160 |
| R0009425 | Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Blonde L, Advances in therapy | 2019 | Other trial | PMID 31359368DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:31359368 |
| R0012646 | Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes. Schmider W, Current medical research and opinion | 2019 | Other | PMID 30550345DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:30550345 |
| R0012665 | Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world. Dailey G, BMJ open diabetes research & care | 2019 | Nonrandomized study | PMID 31114694DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:31114694 |
| R0009175 | Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Rosenstock J, Diabetes, obesity & metabolism | 2018 | Nonrandomized study | PMID 29974618DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:29974618 |
| R0014102 | Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L. Zisman A, Diabetes therapy : research, treatment and education of diabetes and related disorders | 2018 | Randomized trial | PMID 30218434DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:30218434 |
| R0014110 | Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Trujillo JM, Diabetes, obesity & metabolism | 2018 | Other trial | PMID 29923298DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:29923298 |
| R0017480 | iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L. Niemoeller E, Diabetes therapy : research, treatment and education of diabetes and related disorders | 2018 | Other trial | PMID 29143919DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:29143919 |
| R0047494 | A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial Lawrence A. Leiter, Diabetes | 2018 | Other trial | DOI | cites ClinicalTrials.gov:NCT02058160 |
| R0049204 | Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes Pablo Mora, Diabetes | 2018 | Other trial | DOI | cites ClinicalTrials.gov:NCT02058160 |
| R0013638 | Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. Wysham C, Diabetes, obesity & metabolism | 2017 | Randomized trial | PMID 28386990DOI | cites ClinicalTrials.gov:NCT02058160; registry reference DERIVED:28386990 |
| R0044406 | Low incidence of gastrointestinal adverse events over time with a combination of insulin glargine and lixisenatide Bowden Georgina | 2017 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT02058160 |
| R0018472 | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Aroda VR, Diabetes care | 2016 | Randomized trial | PMID 27650977DOI | cites ClinicalTrials.gov:NCT02058160; registry reference RESULT:27650977 |